These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 19394693)

  • 21. Myeloproliferative neoplasm with ABL1/ETV6 rearrangement mimics chronic myeloid leukemia and responds to tyrosine kinase inhibitors.
    Xie W; Wang SA; Hu S; Xu J; Medeiros LJ; Tang G
    Cancer Genet; 2018 Dec; 228-229():41-46. PubMed ID: 30553471
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Recurrent CEP85L-PDGFRB fusion in patient with t(5;6) and imatinib-responsive myeloproliferative neoplasm with eosinophilia.
    Winkelmann N; Hidalgo-Curtis C; Waghorn K; Score J; Dickinson H; Jack A; Ali S; Cross NC
    Leuk Lymphoma; 2013 Jul; 54(7):1527-31. PubMed ID: 23186533
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Syndrome of inappropriate secretion of antidiuretic hormone associated with imatinib.
    Liapis K; Apostolidis J; Charitaki E; Panitsas F; Harhalakis N; Nikiforakis E
    Ann Pharmacother; 2008 Dec; 42(12):1882-6. PubMed ID: 19017824
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [FIP1L1-PDGFRА-positive myeloproliferative disease with eosinophilia: A rare case with multiple organ dysfunction and a response to tyrosine kinase inhibitor therapy].
    Nemchenko IS; Turkina AG; Chelysheva EY; Galstyan GM; Kovrigina AM; Khuazheva NK; Savchenko VG
    Ter Arkh; 2015; 87(12):89-95. PubMed ID: 26978425
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Imatinib: a second look. Longer follow-up in chronic myeloid leukaemia: clear advantages.
    Prescrire Int; 2008 Dec; 17(98):226-8. PubMed ID: 19415889
    [TBL] [Abstract][Full Text] [Related]  

  • 26. p53-Binding protein 1 is fused to the platelet-derived growth factor receptor beta in a patient with a t(5;15)(q33;q22) and an imatinib-responsive eosinophilic myeloproliferative disorder.
    Grand FH; Burgstaller S; Kühr T; Baxter EJ; Webersinke G; Thaler J; Chase AJ; Cross NC
    Cancer Res; 2004 Oct; 64(20):7216-9. PubMed ID: 15492236
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Successful treatment with imatinib mesylate in a case of chronic myeloproliferative disorder with a t(5;12)(q33;p13.1) without eosinophilia.
    Nadal N; Flandrin P; Cornillon J; Delabesse E; Mauvieux L; Olaru D; Morel S; Campos L
    Cancer Genet Cytogenet; 2006 Sep; 169(2):174-5. PubMed ID: 16938578
    [No Abstract]   [Full Text] [Related]  

  • 28. Philadelphia chromosome-negative myeloproliferative neoplasm with a novel platelet-derived growth factor receptor-β rearrangement responsive to imatinib.
    Cornfield D; Shah U; Cross N; Bennett C; Sun G
    J Clin Oncol; 2012 Mar; 30(9):e109-11. PubMed ID: 22331939
    [No Abstract]   [Full Text] [Related]  

  • 29. Relapse of myeloid neoplasm with eosinophilia and PDGFRA rearrangement after imatinib discontinuation in a pediatric patient.
    Rathe M; Schomerus E; Wehner PS; Kristensen TK; Møller MB
    Pediatr Blood Cancer; 2014 Dec; 61(12):2328. PubMed ID: 25175494
    [No Abstract]   [Full Text] [Related]  

  • 30. NDEL1-PDGFRB fusion gene in a myeloid malignancy with eosinophilia associated with resistance to tyrosine kinase inhibitors.
    Byrgazov K; Kastner R; Gorna M; Hoermann G; Koenig M; Lucini CB; Ulreich R; Benesch M; Strenger V; Lackner H; Schwinger W; Sovinz P; Haas OA; van den Heuvel-Eibrink M; Niemeyer CM; Hantschel O; Valent P; Superti-Furga G; Urban C; Dworzak MN; Lion T
    Leukemia; 2017 Jan; 31(1):237-240. PubMed ID: 27573554
    [No Abstract]   [Full Text] [Related]  

  • 31. Myeloproliferative neoplasm with eosinophilia and T-lymphoblastic lymphoma with ETV6-LYN gene fusion.
    Telford N; Alexander S; McGinn OJ; Williams M; Wood KM; Bloor A; Saha V
    Blood Cancer J; 2016 Apr; 6(4):e412. PubMed ID: 27058227
    [No Abstract]   [Full Text] [Related]  

  • 32. Chronic myeloproliferative disorder with ETV6-PDGFRβ fusion gene.
    Tipirneni E; Buttar A; Brettler D; Miron P; Bathini V
    Ann Hematol; 2012 Apr; 91(4):637-8. PubMed ID: 21833478
    [No Abstract]   [Full Text] [Related]  

  • 33. JAK2 inhibitors: not the next imatinib but researchers see other possibilities.
    Garber K
    J Natl Cancer Inst; 2009 Jul; 101(14):980-2. PubMed ID: 19584324
    [No Abstract]   [Full Text] [Related]  

  • 34. [Major molecular response to imatinib in a patient with acute mixed lineage leukemia expressing a novel BCR/ABL transcript].
    Liu HX; Cao XY; Tong CR; Wu T; Wang T; Fan QZ; Wu P; Zhang X; Cai P; Zhu P
    Zhonghua Yi Xue Za Zhi; 2009 Feb; 89(4):220-3. PubMed ID: 19552835
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The interplay of structural information and functional studies in kinase drug design: insights from BCR-Abl.
    Eck MJ; Manley PW
    Curr Opin Cell Biol; 2009 Apr; 21(2):288-95. PubMed ID: 19217274
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Chronic myelogenous leukemia with the e6a2 BCR-ABL and lacking imatinib response: presentation of two cases.
    Vefring HK; Gruber FX; Wee L; Hovland R; Hjorth-Hansen H; Gedde Dahl T; Meyer P
    Acta Haematol; 2009; 122(1):11-6. PubMed ID: 19641300
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Interferon-alpha may restore sensitivity to tyrosine-kinase inhibitors in Philadelphia chromosome positive acute lymphoblastic leukaemia with F317L mutation.
    Potenza L; Volzone F; Riva G; Soverini S; Martinelli S; Iacobucci I; Gnani A; Barozzi P; Forghieri F; Morselli M; Zanetti E; Maccaferri M; Baccarani M; Martinelli G; Torelli G; Luppi M
    Br J Haematol; 2009 Jul; 146(2):227-30. PubMed ID: 19545285
    [No Abstract]   [Full Text] [Related]  

  • 38. Treatment of the myeloid/lymphoid neoplasm with FGFR1 rearrangement with FGFR1 inhibitor.
    Verstovsek S; Subbiah V; Masarova L; Yin CC; Tang G; Manshouri T; Asatiani E; Daver NG
    Ann Oncol; 2018 Aug; 29(8):1880-1882. PubMed ID: 29767670
    [No Abstract]   [Full Text] [Related]  

  • 39. [Pediatric myeloid neoplasms associated with eosinophilia and platelet-derived growth factor receptor beta gene rearrangement: a case report and literature review].
    Zhang XY; Liu TF; Li CW; Li QH; Zhu XF
    Zhonghua Er Ke Za Zhi; 2018 Jan; 56(1):34-38. PubMed ID: 29342995
    [No Abstract]   [Full Text] [Related]  

  • 40. Tumor lysis syndrome after starting treatment with Gleevec in a patient with chronic myelogenous leukemia.
    Al-Kali A; Farooq S; Tfayli A
    J Clin Pharm Ther; 2009 Oct; 34(5):607-10. PubMed ID: 19744017
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.